Note: Descriptions are shown in the official language in which they were submitted.
USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING
PARKINSON'S DISEASE
FIELD OF THE INVENTION
[001] The present disclosure relates to a method for the treatment of
Parkinson's
disease as well as to pharmaceutical dosage forms used in said method.
BACKGROUND OF THE INVENTION
[002] Levodopa ((-)-L-alpha-amino-beta-(3,4-dihydroxybenzene)propanoic acid)
is a
commonly used drug in the treatment of Parkinson's disease (PD). It is
commercially
available as a combination with an aromatic amino acid decarboxylase (AADC)
inhibitor such as carbidopa ((-)-L-alpha-hydrazino-alpha-methyl-beta-(3,4-
dihydroxybenzene)propionic acid) monohydrate) or benserazide hydrochloride (N-
DL-
sery1)-N"-(2,3,4-trihydroxy-benzyl)hydrazine hydrochloride). The combination
of
levodopa with carbidopa is sold under, for instance, the trademarks SINEMET ,
DUODOPA and PARCOPA and the combination with benserazide hydrochloride
is sold under, for instance, the trademark MADOPAR .
[003] Entacapone ((E)-2-cyano-3-(3,4-dihydroxy-5-nitropheny))-N-diethyl-2
propenamide) is a catechol-O-methyl transferase (COMT) inhibitor that is used
in
combination with levodopa and carbidopa or benserazide to treat Parkinson's
disease. It is commercially available as a stand-alone formulation under, for
instance,
the trademarks COMTESS and COMTAN and as a fixed combination
(levodopa:carbidopa:entacapone: 50 mg:12.5 mg:200 mg, 75 mg:18.75 mg:200 mg,
100 mg:25 mg:200 mg, 125 mg:31.25 mg:200 mg, 150 mg:37.5 mg:200 mg and 200
mg:50 mg:200 mg) under, for instance, the trademark STALEVO .
[004] Typically, the proportion of levodopa to carbidopa (when calculated as
anhydrate) or benserazide hydrochloride in commercial formulations is 4:1 (or
sometimes also 10:1 with carbidopa) by weight and the proportion of entacapone
to
carbidopa or benserazide hydrochloride, respectively, is at least 4:1 by
weight. None
of the above-cited products nor any publication, of which applicants are
aware,
discloses the simultaneous or sequential administration of levodopa, carbidopa
(or
1
CA 2784819 2017-11-15
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
benserazide hydrochloride) and entacapone to ,a human in a repeated manner,
wherein the proportion of entacapone to carbidopa is less than 4:1 by weight.
[005] Tolcapone (3,4-dihydroxy-4"-methy1-5-nitro-benzophenone) is another
COMT inhibitor that is used as a 100 mg or 200 mg stand-alone formulation
administered three times daily as an adjunct to the levodopa/carbidopa or
levodopa/benserazide treatment, the proportions of levodopa to the AADC
inhibitor
being the same as those used with entacapone. Tolcapone is sold under
trademark
TASMAR and its preparation has been disclosed in EP 0 237 929.
[006] WO 2007/013830 discloses several COMT inhibitors including BIA 9-
1067 (543-(2,5-dichloro-4,6-dimethy1-1-oxypyridin-3-y1)41,2,4]oxadiazol-5-y11-
3-
nitrobenzene-1,2-diol), which is undergoing clinical evaluation. WO 2000/37423
discloses BIA 3-201 (1-(3,4-dihydroxy-5-nitropheny1)-2-phenyl-ethanone,
nebicapone).
[007] WO 2007/010085 discloses new COMT inhibitor such as (3-chloro-5,6-
dihydroxy-7-nitro-benzo[b]thiophen-2-y1)-morpholin-4-yl-methanone, 3-chloro-
5,6-
dihydroxy-7-nitro-benzo[b]thiophene-2-carboxylic acid diethylamide, (3-chloro-
5,6-
dihydroxy-7-nitro-benzo[b]thiophen-2-y1)-piperidin-1-yl-methanone, 3-chloro-
5,6-
dihydroxy-7-nitro-benzo[b]thiophene-2-carboxylic acid phenylamide, 3-[(3-
chloro-
5,6-dihydroxy-7-nitro-benzo[b]thiophene-2-carbonyl)-amino]-benzoic acid, 4-[(3-
chloro-5,6-dihydroxy-7-nitro-benzo[b]thiophene-2-carbony1)-aminoFbenzoic acid,
3-
chloro-5,6-dihydroxy-7-nitro-benzo[b]thiophene-2-carboxylic acid (4-methoxy-
phenyl)amide, (3-chloro-5,6-dihydroxy-7-nitro-benzo[b]thiophen-2-y1)-(2,6-
dimethyl-
morpholin-4-y1)-methanone, (3-chloro-5,6-dihydroxy-7-nitro-benzo[b]thiophen-2-
y1)-
(4-hydroxy-piperidin-1-y1)-methanone, which are believed to be much more
potent
than entacapone and tolcapone due to their slower elimination via
glucuronidation,
[008] For the purposes of this disclosure, the COMT inhibitors disclosed in
WO 2007/010085 as well as BIA 9-1067 are considered to belong to a class of
"highly potent COMT inhibitors." The predicted standard dose (the dose
recommended to be used together with the above mentioned conventional
proportion of levodopa to carbidopa) for a highly potent COMT inhibitor ranges
from
0.1 mg to 50.
- 2 -
[009] For the purposes of this disclosure, tolcapone and other such COMT
inhibitors, the standard dose of which ranges from more than 50 mg to 200 mg,
are
considered to belong to a class of "moderately potent COMT inhibitors."
SUMMARY OF THE INVENTION
[0010] Deleted.
[0011] The present disclosure provides a method for the treatment of
Parkinson's
disease (PD) comprising simultaneously or sequentially administering to a
patient in
need of treatment of Parkinson's disease
(i) levodopa in an amount ranging from 50 mg to 300 mg,
(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the
proportion
of entacapone to carbidopa ranges from 0.33:1.0 to 3.2:1.0 by weight, a
moderately
potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the
proportion of said COMT inhibitor to carbidopa ranges from 0.16:1.0 to
3.08:1.0 by
weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to
100
mg, wherein the proportion of said COMT inhibitor to carbidopa ranges from
0.006:1.0 to 1.54:1.0 by weight.
[0011a]ln a particular embodiment, the present disclosure provides levodopa,
carbidopa and entacapone for use in the manufacture of a medicament for the
treatment of Parkinson's disease wherein said levodopa, carbidopa and
entacapone
are suitable for simultaneous or sequential oral administration to a patient
in the
following amounts:
(i) levodopa in an amount ranging from 75 mg to 175 mg,
(ii) carbidopa in an amount ranging from 65 mg to 105 mg, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg,
3
CA 2734819 2017-07-21
wherein the proportion of entacapone to carbidopa ranges from 0.95:1.0 to
3.08:1.0
by weight.
[0012] The present disclosure also provides a dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 300 mg,
(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the
proportion
of entacapone to carbidopa in said dosage form ranges from 0.33:1.0 to 3.2:1.0
by
weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to
200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said
dosage
form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT
inhibitor
in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT
inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0
by
weight.
[0012a] In a particular embodiment, the present disclosure provides an
oral
dosage form comprising
(i) levodopa in an amount ranging from 75 mg to 175 mg,
(ii) carbidopa in an amount ranging from 65 mg to 105 mg and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.95:1.0
to
3.08:1.0 by weight.
3a
CA 2734819 2017-07-21
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
[0013] Patients that may benefit the most from the invention are those
whose
Parkinson's disease symptoms or motor complications such as on/off
fluctuations
have not been adequately controlled with their existing levodopa-AADC
inhibitor
therapy. Thus, a typical patient to be treated is an adult patient with
Parkinson's
disease having symptoms of end-of-dose wearing off.
BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 shows the mean levodopa plasma concentrations (ng/ml) by
study treatments:
A: Entacapone 200 mg + levodopa 100 mg + carbidopa 25 mg
B: Entacapone 200 mg + levodopa 100 mg + carbidopa 50 mg
C: Entacapone 200 mg + levodopa 100 mg + carbidopa 100 mg
E: Levodopa 100 mg + carbidopa 25 mg
F: Levodopa 100 mg + carbidopa 50 mg
G: Levodopa 100 mg + carbidopa 100 mg.
[0015] Figure 2 shows the mean carbidopa plasma concentrations (ng/ml) by
study treatments:
A: Entacapone 200 mg + levodopa 100 mg + carbidopa 25 mg
B: Entacapone 200 mg + levodopa 100 mg + carbidopa 50 mg
C: Entacapone 200 mg + levodopa 100 Mg + carbidopa 100 mg
E: Levodopa 100 mg + carbidopa 25 mg
F: Levodopa 100 mg + carbidopa 50 mg
G: Levodopa 100 mg + carbidopa 100 mg.
[0016] Figure 3 shows mean levodopa concentrations in human with increased
carbidopa dose and with increasing COMT-inhibition either by increasing the
entacapone dose or by using the moderately potent COMT inhibitor, tolcapone.
DETAILED DESCRIPTION OF THE INVENTION
[0017] The most
effective therapy for symptom control in Parkinson's Disease
is levodopa therapy. However, with disease progression and long-term levodopa
treatment, PD patients frequently experience motor complications, including
wearing-
- 4 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
off symptoms such as "end-of-dose wearing off' symptoms, "early morning
dystonia"
and "on/off fluctuations," and dyskinesia.
[0018] During end-of-dose wearing off, the effect of a dose of a PD drug
decreases (wears off), the drug concentration decreases in plasma and
subsequently in the brain, and the severity of PD symptoms, e.g.,
bradykinesia,
rigidity, and resting tremor, are increased before the next dose is taken.
Partly
related to the motor symptoms and partly to the autonomic dysfunction, a PD
patient
with "end-of-dose wearing off' or "on/off fluctuations" may experience poor
gastrointestinal tract mobility and swallowing difficulties.
[0019] In addition to the symptoms relating to motor function, the wearing-
off
symptoms may also include non-motor symptoms such as anxiety and pain. The
reasons for the fluctuation episodes are not completely understood but may be,
in
part, related to oscillating plasma levels of levodopa in turn leading to
intermittent or
pulsatile stimulation of striatial dopamine receptors in the brain. End-of-
dose
wearing off symptoms or on/off fluctuations comprise alternations between
periods of
relatively good mobility ("on" periods) and periods of relatively impaired
motor
function ("off' periods) often associated with simultaneous non-motor
symptoms.
Dyskinesia are involuntary movements in the body of a PD patient often
associated
with high maximum or peak concentrations of a PD drug, such as levodopa. Thus,
there is a continuing need to improve the present levodopa therapies by
striving
towards more steady plasma levels of levodopa and subsequently more continuous
dopaminergic stimulation.
[0020] The inventors have surprisingly found that, in combination with a
COMT
inhibitor, AADC inhibition is not saturated by the currently used carbidopa
dose, as
with levodopa-carbidopa combination alone, but may be further enhanced by
increased carbidopa doses, which may lead to improved levodopa
pharmacokinetics
and metabolism and subsequently may lead to improved control of PD symptoms
and motor complications.
[0021] Unlike in traditional levodopa therapy, there may be no need to
maintain
a standard levodopa/carbidopa ratio (such as 4:1) across all dosage strengths,
when
using the treatment according to the invention. Furthermore, in combination
with a
COMT inhibitor, increased carbidopa doses may potentiate the pharmacodynamic
- 5 -
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
effect on the AADC inhibition and subsequently may increase levodopa AUC
throughout the dosing period despite the decreasing carbidopa plasma
concentrations towards the end of said period. This is because by the
increased
carbidopa dose in the presence of a COMT inhibitor Cmin and AUC of levodopa
are
significantly increased. This means that, when a COMT inhibitor is given in
conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor,
such
as carbidopa, plasma levels of levodopa are higher and more sustained with the
increased carbidopa dose than after administration of levodopa and an aromatic
amino acid decarboxylase inhibitor alone.
[0022] It is believed that, at a given daily frequency of levodopa
administration,
those more sustained plasma levels of levodopa resulting from an increased
carbidopa dose yield more constant dopaminergic stimulation in the brain,
leading to
improved control of the signs and symptoms of Parkinson's Disease, especially
in
end-of-dose wearing off and on/off fluctuations and in. As maximum
concentrations
of levodopa are not clinically significantly increased, the improved control
of the
signs and symptoms of Parkinson's Disease are not accompanied by increase of
dopaminergic adverse effects or motor complications, such as dyskinesia, which
would require reducing of the levodopa dose.
[0023] Furthermore, as the effect on levodopa is not sensitive to decreased
plasma concentration of carbidopa towards the end of said period, no
accumulation
of carbidopa concentrations in plasma is seen. In fact, in the study, the
concentrations were decreasing towards the end of the dosing period, which
will
reduce the probability of carbidopa passing the blood brain barrier and
inhibiting
AADC in the brain followed by subsequent increase of CNS side effects.
[0024] In combination with increased carbidopa dose, the COMT-inhibitor
dose
can also be reduced without significantly reducing AUC of levodopa. Reducing
the
amount of COMT-inhibitor would allow a smaller tablet size which would in turn
benefit especially patients with swallowing difficulties. This would also be
advantageous to reduce the risk of COMT inhibitor related gastrointestinal
irritation
and urine discoloration.
[0025] In combination with increased carbidopa dose, the COMT-inhibitor
dose
or potency can also be increased to an extent that will not significantly
increase
- 6 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
Cmax but will increase AUC of levodopa. Increasing the COMT-inhibitor potency
would allow better control of PD symptoms. This would be advantageous to PD
patients with wearing-off symptoms such as end-of-dose wearing off, early
morning
dystonia, and on/off fluctuations.
[0026] Thus, the present disclosure provides a method for the treatment of
Parkinson's disease comprising simultaneously or sequentially administering to
a
patient in need of treatment of Parkinson's disease
(i) levodopa in an amount ranging from 50 mg to 300 mg,
(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the
proportion
of entacapone to carbidopa ranges from 0.33:1.0 to 3.2:1.0 by weight, a
moderately
potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the
proportion of said COMT inhibitor to carbidopa ranges from 0.16:1.0 to
3.08:1.0 by
weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to
100 mg,
wherein the proportion of said COMT inhibitor to carbidopa ranges from
0.006:1.0 to
1.54:1.0 by weight.
[0027] In one embodiment, the patient to be treated is an adult patient
with
Parkinson's disease experiencing symptoms of end-of-dose wearing off.
[0028] The present disclosure also provides a dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 300 mg,
(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the
proportion
of entacapone to carbidopa in said dosage form ranges from 0.33:1.0 to 3.2:1.0
by
weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to
200
mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage
form
ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor
in an
amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT
inhibitor
to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight.
[0029] The present disclosure also provides levodopa, an aromatic amino
acid
decarboxylase inhibitor, and entacapone for use in a method of treatment of
- 7 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
Parkinson's disease by simultaneous or sequential administration to a patient
of
(i) levodopa in an amount ranging from 50 mg to 300 mg,
(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the
proportion
of entacapone to carbidopa ranges from 0.33:1.0 to 3.2:1.0 by weight, a
moderately
potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the
proportion of said COMT inhibitor to carbidopa ranges from 0.16:1.0 to
3.08:1.0 by
weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to
100 mg,
wherein the proportion of said COMT inhibitor to carbidopa ranges from
0.006:1.0 to
1.54:1.0 by weight, optionally wherein carbidopa is replaced by a
therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor.
[0030] The present disclosure also provides use of levodopa, an aromatic
amino acid decarboxylase inhibitor, and entacapone in the manufacture of a
medicament for the treatment of Parkinson's disease by simultaneous or
sequential
administration to a patient of (i) levodopa in an amount ranging from 50 mg to
300
mg,
(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the
proportion
of entacapone to carbidopa ranges from 0.33:1.0 to 3.2:1.0 by weight, a
moderately
potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the
proportion of said COMT inhibitor to carbidopa ranges from 0.16:1.0 to
3.08:1.0 by
weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to
100 mg,
wherein the proportion of said COMT inhibitor to carbidopa ranges from
0.006:1.0 to
1.54:1.0 by weight, optionally wherein carbidopa is replaced by a
therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor.
[0031] The present disclosure also provides a dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 300 mg,
(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the
proportion
- 8 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
of entacapone to carbidopa in said dosage form ranges from 0.33:1.0 to 3.2:1.0
by
weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to
200
mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage
form
ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor
in an
amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT
inhibitor
to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight,
for
simultaneous or sequential use in the treatment of Parkinson's disease.
[0032] The present disclosure also provides a kit for simultaneous or
sequential
administration of levodopa, carbidopa or a therapeutically equivalent amount
of
another aromatic amino acid decarboxylase inhibitor, and entacapone, a
moderately
potent COMT inhibitor, or a highly potent COMT inhibitor, comprising:
(i) levodopa in an amount ranging from 50 mg to 300 mg;
(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor; and
(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the
proportion
of entacapone to carbidopa in said administration ranges from 0.33:1.0 to
3.2:1.0
by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg
to
200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said
administration ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent
COMT
inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of
said
COMT inhibitor to carbidopa in said administration ranges from 0.006:1.0 to
1.54:1.0
by weight, wherein the kit may further comprise instructions for the
simultaneous or
sequential administration of the levodopa, carbidopa or a therapeutically
equivalent
amount of another aromatic amino acid decarboxylase inhibitor, and entacapone,
a
moderately potent COMT inhibitor, or a highly potent COMT inhibitor in the
treatment
of Parkinson's disease.
[0033] In one embodiment, levodopa is present in an amount ranging from 50
mg to 200 mg, carbidopa is present in an amount ranging from 65 mg to 125 mg,
and entacapone is present in an amount ranging from 100 mg to 200 mg, wherein
the proportion of entacapone to carbidopa ranges from 0.8:1.0 to 3.08:1.0 by
weight.
[0034] In one embodiment, levodopa is present in an amount ranging from 75
mg to 175 mg, carbidopa is present in an amount ranging from 65 mg to 105 mg,
- 9 -
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
and entacapone is present in an amount ranging from 100 mg to 200 mg, wherein
the proportion of entacapone to carbidopa ranges from 0.95:1.0 to 3.08:1.0 by
weight.
[0035] In one embodiment of the invention, levodopa is present in an amount
ranging from 50 mg to 300 mg, for instance from 50 mg to 200 mg, such as from
75
mg to 125 mg, for example 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, or 200 mg, for
example 75 mg, 100 mg, 125 mg, 150 mg.
[0036] In one embodiment, carbidopa is present in an amount ranging from 65
mg to 150 mg, for instance from 65 mg to 125 mg, such as from 65 mg to 105 mg,
for example 65 mg, 80 mg, 85 mg, 105 mg, or 125 mg.
[0037] In one embodiment, entacapone is present in an amount ranging from
50 mg to 300 mg, for instance from 50 mg to 200 mg, such as from 100 mg to 200
mg, for example 100 mg, 150 mg or 200 mg.
[0038] In one embodiment, the moderately potent COMT inhibitor, such as
tolcapone, is present in an amount ranging from 25 mg to 200 mg, for instance
from
50 mg to 200 mg, such as from 50 mg to 100 mg, for example 50 mg, 100 mg, or
200 mg.
[0039] In one embodiment, the highly potent COMT inhibitor, such as BIA 9-
1067, is present in an amount ranging from 1 mg to 100 mg, for instance from 1
mg
to 50 mg, such as from 1 mg to 25 mg, for example 1 mg, 2.5 mg, 5 mg, 10 mg,
or
25 mg.
[0040] In one embodiment, carbidopa is replaced by a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, such
as
for instance with benserazide.
[0041] In one embodiment, the treatment and/or the dosage form is oral.
[0042] In one embodiment the treatment comprises administering orally a
solid
combination formulation.
[0043] In a further embodiment, the oral dosage form is an oral solid
combination formulation
[0044] In one embodiment, the proportion of entacapone to carbidopa ranges
from 0.33:1.0 to 3.08:1.0 by weight, for instance from 0.8:1.0 to 2.35:1.0 by
weight.
-10-
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
[0045] In one embodiment, the proportion of entacapone to carbidopa is
0.66:1.0, 0.80:1.0, 0.95:1.0, 1.18:1.0, 1.33:1.0, 1.54:1.0, 1.6:1.0, 1.9:1.0,
2.35:1.0,
2.5:1.0, or 3.08:1.0 by weight.
[0046] In one embodiment, the proportions of entacapone and carbidopa are
100 mg:125 mg, 100 mg:105 mg, 100 mg:85 mg, 100 mg:80 mg, 100 mg:65 mg, 200
mg:125 mg, 200 mg:105 mg, 200 mg:85 mg, 200 mg:80 mg, 200 mg:65 mg.
[0047] In one embodiment, the proportion of levodopa to carbidopa ranges
from
0.4:1.0 to 3.1:1.0 by weight, for instance from 0.48:1.0 to 1.91:1.0 by
weight.
[0048] In one embodiment, the proportions of levodopa and carbidopa are 50
mg:45 mg, 50 mg:65 mg, 50 mg:80 mg, 50 mg:85 mg, 50 mg:105 mg, 50 mg:125
mg, 75 mg:45 mg, 75 mg:65 mg, 75 mg:80 mg, 75 mg:85 mg, 75 mg:105 mg, 75
mg:125 mg, 100 mg:45 mg, 100 mg:65 mg, 100 mg:80 mg, 100 mg:85 mg, 100
mg:105 mg, 100 mg:125 mg, 125 mg:45 mg, 125 mg:65 mg, 125 mg:80 mg, 125
mg:85 mg, 125 mg:105 mg, 125 mg:125 mg, 150 mg:45 mg, 150 mg:65 mg, 150
mg:80 mg, 150 mg:85 mg, 150 mg:105 mg, 150 mg:125 mg, 200 mg:65 mg, 200
mg:80 mg, 200 mg:85 mg, 200 mg:105 mg, or 200 mg:125 mg.
[0049] In one embodiment, the proportions of levodopa, carbidopa and
entacapone are 50 mg:65 mg:200 mg, 50 mg:80 mg:200 mg, 50 mg:85 mg:200 mg,
50 mg:105 mg:200 mg, 50 mg:125 mg:200 mg, 75 mg:65 mg:200 mg, 75 mg:80
mg:200 mg, 75 mg:85 mg:200 mg, 75 mg:105 mg:200 mg, 75 mg:125 mg:200 mg,
100 mg:65 mg:200 mg, 100 mg:80 mg:200 mg, 100 mg:85 mg:200 mg, 100 mg:105
mg:200 mg, 100 mg:125 mg:200 mg, 125 mg:65 mg:200 mg, 125 mg:80 mg:200 mg,
125 mg:85 mg:200 mg, 125 mg:105 mg:200 mg, 125 mg:125 mg:200 mg, 150 mg:65
mg:200 mg, 150 mg:80 mg:200 mg, 150 mg:85 mg:200 mg, 150 mg:105 mg:200 mg,
150 mg:125 mg:200 mg, mg, 200 mg:65 mg:200 mg, 200 mg:80 mg:200 mg, 200
mg:85 mg:200 mg, 200 mg:105 mg:200 mg, or 200 mg:125 mg:200 mg.
[0050] In one embodiment, the proportions of levodopa, carbidopa and
entacapone are 50 mg:65 mg:200 mg, 50 mg:80 mg:200 mg, 50 mg:85 mg:200 mg,
50 mg:105 mg:200 mg, 75 mg:65 mg:200 mg, 75 mg:80 mg:200 mg, 75 mg:85
mg:200 mg, 75 mg:105 mg:200 mg, 100 mg:65 mg:200 mg, 100 mg:80 mg:200 mg,
100 mg:85 m9:200 mg, 100 mg:105 mg:200 mg, 125 mg:65 mg:200 mg, 125 mg:80
mg:200 mg, 125 mg:85 mg:200 mg, 125 mg:105 mg:200 mg, 150 mg:65 mg:200
- 11 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
mg, 150 mg:80 mg:200 mg, 150 mg:85 mg:200 mg, 150 mg:105 mg:200 mg, 200
mg:65 mg:200 mg, 200 mg:80 mg:200 mg, 200 mg:85 mg:200 mg, or 200 mg:105
mg:200 mg.
[0051] In one embodiment, the proportions of levodopa, carbidopa and
entacapone are 75 mg:65 mg:200 mg, 75 mg:85 mg:200 mg, 75 mg:105 mg:200
mg, 100 mg:65 mg:200 mg, 100 mg:85 mg:200 mg, 100 mg:105 mg:200 mg, 125
mg:65 mg:200 mg, 125 mg:85 mg:200 mg, 125 mg:105 mg:200 mg, 150 mg:65
mg:200 mg, 150 mg:85 mg:200 mg, or 150 mg:105 mg:200 mg.
[0052] In one embodiment of the invention, the daily dose of levodopa
ranges
from 150 mg to 1500 mg, for instance from 300 mg to 1250 mg, such as from 300
mg to 900 mg, wherein the total number of daily doses ranges from 3 to 10, for
instance from 3 to 7, such as from 4 to 6, such as 4 or 5 or 6.
[0053] In one embodiment of the invention, the daily dose of carbidopa
ranges
from 135 mg to 1250 mg, for instance from 195 mg to 1050 mg, such as form 255
mg to 850 mg, wherein the total number of daily doses ranges from 3 to 10, for
instance from 3 to 7, such as from 4 to 6, such as 4 or 5 or 6.
[0054] In one embodiment of the invention the highly potent COMT inhibitor
is
BIA 9-1067 (543-(2,5-dichloro-4,6-dimethy1-1-oxypyridin-3-y1)41,2,4]oxadiazol-
5-y11-
3-nitrobenzene-1,2-diol)In one embodiment the daily dose of BIA 9-1067 is 25
mg or
50 mg given once-a-day. BIA 9-1067 is a poorly soluble drug. WO 2009/108077
discloses a solid dosage form for the release of a poorly soluble active
pharmaceutical ingredient such as BIA 9-1067.
[0055] In one embodiment the proportion of BIA 9-1067 to carbidopa ranges
from 0.01:1.0 to 0.16:1.0 by weight, for instance from 0.02:1.0 to 0.1:1.0 by
weight.
[0056] In one embodiment the proportions of BIA 9-1067 and carbidopa are
2.5
mg:65 mg, 2.5 mg:85 mg, 2.5 mg:105 mg, 5.0 mg:65 mg, 5.0 mg:85 mg, 5.0 mg:105
mg, 10.0 mg:65 mg, 10.0 mg:85 mg or 10.0 mg:105 mg.
[0057] In one embodiment the proportions of levodopa, carbidopa and BIA 9-
1067 are 75 mg:65 mg:2.5 mg, 75 mg:85 mg:2.5 mg, 75 mg:105:2.5 mg, 100 mg:65
mg:2.5 mg, 100 mg:85 mg:2.5 mg, 100 mg:105 mg:2.5 mg, 125 mg:65 mg:2.5 mg,
125 mg:85 mg:2.5 mg, 125 mg:105 mg:2.5 mg, 150 mg:65 mg:2.5 mg, 150 mg:85
mg:2.5 mg, 150 mg:105 mg:2.5 mg, 75 mg:65 mg:5.0 mg, 75 mg:85 mg:5.0 mg, 75
- 12 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
mg:105:5.0 mg, 100 mg:65 mg:5.0 mg, 100 mg:85 mg: 5.0 mg, 100 mg:105 mg:5.0
mg, 125 mg:65 mg:5.0 mg, 125 mg:85 mg:5.0 mg, 125 mg:105 mg:5.0 mg, 150
mg:65 mg:5.0mg, 150 mg:85 mg:5.0 mg, 150 mg:105 mg:5.0 mg, 75 mg:65 mg:10.0
mg, 75 mg:85 mg:10.0 mg, 75 mg:105:10.0 mg, 100 mg:65 mg:10.0 mg, 100 mg:85
mg: 10.0 mg, 100 mg:105 mg:10.0 mg, 125 mg:65 mg:10.0 mg, 125 mg:85 mg:10.0
mg, 125 mg:105 mg:10.0 mg, 150 mg:65 mg:10.0mg, 150 mg:85 mg:10.0 mg, 150
mg:105 mg:10.0 mg.
[0058] In one embodiment of the invention, the daily dose of entacapone
ranges from 150 mg to 2000 mg, for instance from 300 mg to 2000 mg, such as
from
300 mg to 1600 mg, wherein the total number of daily doses ranges from 3 to
10, for
instance from 3 to 8, such as from 4 to 6, such as 4 or 5 or 6. In one
embodiment of
the invention, the daily dose of tolcapone or another moderately potent COMT
inhibitor ranges from 75 mg to 1200 mg, for instance from 150 mg to 800 mg,
such
as from 300 mg to 600 mg, wherein the total number of daily doses ranges from
3 to
10, for instance from 3 to 7, such as from 3 to 5, such as 3 or 4 or 5. In one
embodiment of the invention, the daily dose of a highly potent COMT inhibitor
ranges
from 1 mg to 500 mg, for instance from 5 mg to 100 mg, such as from 10 mg to
100
mg, wherein the total number of daily doses ranges from 1 to 10, for instance
from 1
to 7, such as from 1 to 3, such as 1 or 2 or 3.
[0059] It is to be understood that whenever a given amount of levodopa,
carbidopa, benserazide, or other AADC inhibitor or entacapone or other COMT
inhibitor is mentioned herein in the context of this disclosure it is meant to
comprise
also an equivalent amount of a pharmaceutically acceptable salt, prodrug
(including
ester) or hydrate.
[0060] It is also to be understood that the amounts and ranges mentioned in
this disclosure apply to all embodiments disclosed herein whether methods
(i.e.
methods for the treatment or methods for the manufacture) or dosage forms.
Definitions
[0061] The term "treatment of Parkinson's Disease" refers to relieving
and/or
delaying of the worsening of one of more of the symptoms and/or motor
complications related to idiopathic Parkinson's Disease, e.g. bradykinesia,
rigidity,
and resting tremor.
- 13 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
[0062] The term "adult patient" means a patient 18 years of age or older.
[0063] The term "symptoms of end-of-dose wearing-off' refers to the
shortening
of the duration of the motor response after a PD drug intake and increasing
the
severity of e.g. bradykinesia, rigidity, and resting tremor. The term
comprises the
so-called predictable end-of-dose motor fluctuations characterised by end-of-
dose
failure of the symptom control. End-of-dose wearing-off symptoms may also
include
fluctuating non-motor symptoms, such as anxiety and pain. Motor complications
may also include rapid and unpredictable swings from mobility to immobility
("on-off'
phenomenon).
[0064] The term "simultaneous" or "simultaneously" refers to administration
of
the disclosed drug substances at the same time in separate formulations or as
a
combination formulation, i.e. in a single dosage form.
[0065] The term "sequential" or "sequentially" refers to administration of
the
disclosed drug substances one after the other, i.e., not at the same time, in
two or
more separate dosage forms, for example entacapone may be administered as a
separate dosage form and levodopa and carbidopa may be administered in a
combination formulation, or carbidopa may be administered, followed by
levodopa,
then by entacapone. If the disclosed drug substances are administered
sequentially,
then typically administration of the last drug substance is begun an hour or
less,
generally 30 minutes or less, after administration of the first drug substance
is
begun.
[0066] The term "oral solid dosage form" refers to a single or multi-unit
solid
oral dosage form. A single oral dosage form may be a combination formulation,
such as a tablet, which comprises two or more of the drug substances. In one
embodiment the single oral dosage form is a combination formulation, such as a
tablet, which comprises all of the drug substances. A multi-unit solid oral
dosage
form may be a dosage form comprising a plurality of oral solid units in the
form of
small particles (for instance a capsule or sachet filled with minitablets,
granules or
pellets) which, when taken simultaneously or sequentially, provide a unit
dose. The
terms "multiple-unit" or "multi-particulate" oral dosage form may also be used
to refer
to such a multi-unit solid oral dosage form. The particles may be also be used
as
such in a so-called sprinkle form that can be sprinkled directly onto food or
liquids for
-14-
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
easy ingestion. Multiple-unit dosage forms have been accepted to provide
advantages over single unit dosage forms. The pharmacokinetics of the drug
release
from a multiple unit dosage form is more uniform than from the single unit
dosage
form, because the pharmacokinetics of the drug release from a multiple unit
dosage
form is the average value of the kinetics of the drug release from individual
subunits.
The units of a multiple unit dosage form may scatter freely in the
gastrointestinal
tract and act like liquids, leaving the stomach within a short period of time,
which
results in improved biopharmaceutical characteristics, such as improved
bioavailability, reduced food effect on plasma profiles and ultimately reduced
variability of plasma profiles and a lower possibility of local irritation in
gastrointestinal tract. In addition, a multi-unit solid oral dosage form may
be
individual tablets that contain the drug substances. For example, a multi-unit
solid
oral dosage form can include entacapone in one tablet and a separate tablet
containing levodopa and carbidopa.
[0067] The terms "repeated dose" and "in a repeated manner" refers to
multiple
administration of a drug during a day, usually from at least 3 up to 10 times
a day
depending on the severity of the disease of a patient with Parkinson's Disease
and
on the subsequent need of levodopa. For instance, levodopa is usually
administered
in a repeated manner and simultaneously or sequentially with an AADC
inhibitor.
However, a highly potent COMT inhibitor may be administered in combination
with
repeated dose levodopa and AADC inhibitor only once a day or even less
frequently
and a moderately potent COMT inhibitor may be administered one to three times
per
day.
[0068] The "standard dose" may be used to determine whether a COMT
inhibitor may be considered to be a highly potent inhibitor or a moderately
potent
inhibitor. As potency increases, less inhibitor is required to reach 80%
inhibition of
soluble COMT in human erythrocytes (Shultz, E. and Nissinen, E., Biomedical
Chromatography, Vol. 3, No. 2, 1989, 64-67 and Nohta, H. et al, Journal of
Chromatography, 308 (1984) 93-100). For example, a moderately potent COMT
inhibitor will require more than 200 mg in a single dose to reach 80 %
inhibition,
typically from more than 200 mg to 800 mg in a single dose. A highly potent
inhibitor
will need200 mg or less in a single dose to reach 80 % inhibition. A more
potent
- 15 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
inhibitor will also provide effective inhibition for a longer period of time.
Thus, a
moderately potent inhibitor when administered in a 200 mg dose will maintain
40 %
or more effective inhibition of soluble COMT in human erythrocytes for from 2
hours
to less than 8 hours, typically from 3 to 6 hours. A highly potent inhibitor
when
administered in a dose of 100 mg will maintain 40 % or more effective
inhibition of
soluble COMT in human erythrocytes for 8 hours or more. Suitable conditions
for
measuring effective inhibition of soluble COMT in human erythrocytes are
described
in Keranen, T. et al, Eur. J. Clin. Pharmcol (1994) 46:151-157 and Dingemanse,
J. et
al, Clinical Pharmacology & Therapeutics, May 1995, 508-517).
[0069] The term "pharmaceutically acceptable salt" refers to a salt of a
compound that is pharmaceutically acceptable and that possesses the desired
pharmacological activity of the parent compound. Representative examples of
pharmaceutically acceptable salts include, but are not limited to, acid
addition salts
with inorganic or organic acids, for instance, chlorides, bromides, sulfates,
nitrates,
phosphates, sulfonates, methane sulfonates, formates, tartrates, maleates,
citrates,
benzoates, salicylates, ascorbates, acetates, and oxalates. The
pharmaceutically
acceptable form can be in the form of an anhydrate or a hydrate.
[0070] The term "prod rug" refers to a derivative of a drug substance which
releases said active parent drug substance in vivo when such prodrug is
administered to a patient. There are several publications disclosing different
prodrugs of levodopa, for instance, levodopa methyl ester has been under
development by Chiesi under trademark LEVOMET , an ethylester has been
disclosed in U.S. Patent No. 5,607,969 and more complex esters have been
disclosed in EP 0 309 827 B, WO 2005/121069 and WO 2007/067495. Also, various
carbidopa prodrugs have been disclosed e.g. in GB 940,596 and WO 2004/052841.
[0071] The term "ester" refers to an ester of a compound that is
pharmaceutically acceptable and that possesses the desired pharmacological
activity of the parent compound. Such esters may be prepared by known methods
using pharmaceutically acceptable acids that are conventional in the field of
pharmaceuticals. Non-limiting examples of these esters include esters of
aliphatic or
aromatic alcohols. Representative examples of pharmaceutically acceptable
esters
include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl,
iso-butyl,
-16-
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
sec-butyl, tert-butyl, and benzyl esters. There are several publications
disclosing
different esters of levodopa, for instance, several levodopa esters have been
disclosed in EP 309 827, an ethyl ester has been disclosed in U.S. Patent No.
5,607,969 and the methyl ester has been under development by Chiesi under
trademark LEVOMET . Also various carbidopa esters have been disclosed e.g. in
GB 940,596. The pharmaceutically acceptable form can be in the form of an
anhyd rate or hydrate.
[0072] The term "a therapeutically equivalent amount" as used herein refers
to
an amount of an aromatic amino acid decarboxylase inhibitor other than
carbidopa
that is capable of causing a similar therapeutic response as the dose of
carbidopa,
when used according to the present disclosure. For example, 50 mg of
benserazide
hydrochloride is considered to be capable of causing a similar therapeutic
response
as 50 mg of carbidopa, when used according to the present disclosure.
[0073] The terms "substantially separated" and "substantial separation"
refer to
that a considerable or ample amount of said drug substance is kept apart from
the
other drug substance(s), for example, that a considerable amount of carbidopa
is
kept apart from entacapone. There may be several ways to accomplish said
separation, for example, by granulating all or at least one of the drug
substances
separately. No specific separation layer is needed to cause said substantial
separation. It is also to be noted that even though all drug substances would
be
granulated separately, there will always be small amounts of said drug
substance as
a powder. In one embodiment, before granulating and incorporating a drug
substance in a single dosage unit with other drug substances, they may undergo
pre-processing in a manner indicated below.
[0074] The term "substantial portion" refers to that at least 80 % of said
drug
substance is handled using the technology in question. For instance,
granulating a
substantial portion of carbidopa means that from 80 c)/0 to 100 % is
granulated. If 90
% is granulated, then 10 % is added as such. The term "granule" refers to a
pharmaceutical formulation whereby the ingredients have been mixed together in
order to intimately and evenly disperse the drug substance(s) within some or
all of
the other ingredients and to increase the particle size. Well known techniques
are
- 17 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
known in the pharmaceutical industry and can be selected from wet, melt
granulation
or dry granulation.
[0075] The terms "granulating" and "granulation" refer to methods, wherein
one
or more drug substances are brought into contact with at least one
pharmaceutically
acceptable excipient and granulated. The granulation method may be any
granulation method known in the art such as dry granulation, melt granulation
or wet
granulation or the like. All unit operations typically needed to perform
granulation,
such as sieving and drying are meant to be included in said granulation step
in the
context of this disclosure. Furthermore, it is possible to coat the granules
made
according to the invention', for instance, when they are intended to be
administered
to the patient as such. Suitable granulation methods have been described, for
instance in the book: The Theory and Practice of Industrial Pharmacy 3rd
edition,
Lachman L, Lieberman HA and Kanig JL, Lea & Febiger, Philadelphia, 1986 and
the
Handbook of Pharmaceutical Excipients 5th edition, edited by Rowe RC, Sheskey
PJ
and Owen SC, Pharmaceutical Press, 2006.The details of the pharmaceutically
acceptable excipients used therein have been described, for instance in
Pharmaceutics, The Science of Dosage Form Design, 2nd edition. AuIton ME,
Churchill Livingstone, 2002. Suitable melt granulation technologies have been
described, for instance, in Handbook of Pharmaceutical Granulation Technology,
Ed.
by Dilip M. Parikh, Marcel Dekker, Inc. New York, 2" print, 1997. The drug
substances to be used in the granulation method may be pre-processed before
the
granulation. Pre-processing may also generally be applied to drug substances
before formulating into a dosage form without granulation. For example, a drug
substance in the form of a powder may be pre-processed before formulation into
a
dosage form.
[0076] The terms "pre-processed" and "pre-processing" refer to pre-
treatment
of each of the drug substances, either individually or together with another
drug
substance, before further processing, such as before granulation or before
formulating a powder into a dosage form. Suitable pre-processing methods can
be,
for example, sieving, de-dusting, gas treatment, conditioning, milling and
optionally
mixing, de-aggregation, de-agglomeration or treatment with pharmaceutically
acceptable excipients, for example, with glidants such as colloidal silicon
dioxide.
- 18-
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
[0077] The term "mixing" and "preparing a mixture" refer to the meaning
used in
the art of manufacturing pharmaceutical dosage forms Suitable mixing
technologies
have been described, for example in the above mentioned handbooks.
[0078] The term "bilayered tablet" refers to a tablet, wherein there are
two
layers horizontally on the top of each other or there is an inner core
comprising either
one or two of the drug substances and an outer layer comprising at least one
drug
substance. For example, there may be an outer layer comprising carbidopa and
levodopa or carbidopa alone and an inner core comprising entacapone and
levodopa
or entacapone alone. It is also possible to divide one or more drug substances
between two layers, for instance, carbidopa may be divided between the outer
layer
and the inner core. This type of tablets and the preparation thereof have been
described, for instance, in WO 2008/053297. Other suitable technologies have
been
described, for instance in the book: The Theory and Practice of Industrial
Pharmacy
3rd edition, Lachman L, Lieberman HA and Kanig JL, Lea & Febiger,
Philadelphia,
1986. It is to be noted that there may be always one or more inert layers
(e.g. layers
prepared without separately adding a drug substance) in such a bilayered
tablet.
Likewise, it is possible that there is an inert inner core, for instance, a
non-pareil
inside the tablet.
[0079] The terms "trilayered tablet" and "multilayered" tablets refer to
tablets,
wherein there are three or more layers horizontally on the top of each other
or there
is an inner core or layer comprising one of the drug substances a second layer
comprising another drug substance and a third layer comprising the third drug
substance. For example, there may be an outer layer comprising carbidopa and
the
next layer comprising levodopa and an inner core or layer comprising
entacapone. It
is also possible to divide one or more drug substance into several layers, for
instance, carbidopa may be divided between the outer layer and the second
layer.
Other suitable technologies have been described, for instance in the book:
Pharmaceutical Dosage Forms and Drug Delivery Systems,7t1' edition, Ansel! HC,
Allen LV and Popovich NG, Lippincott Williams & Wilkins,1999. It is to be
noted that
there may be always one or more inert layers (e.g. layers prepared without
separately adding a drug substance) in such a trilayered or multilayered
tablet.
- 19 -
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
Likewise, it is possible that there is an inert inner core, for instance, a
non-pareil
inside the tablet.
[0080] The term "minitablet" refers to a compressed pharmaceutical
formulation
that has dimensions of length and breadth (or, depending on its shape, a
diameter)
each equal to or less than 5 mm.
[0081] The term "pellet" refers to a substantially spherical solid particle
whose
diameter size may range from about 100 microns to about 3 mm that has been
made
by layering onto a particle (for instance, on a non-pareil) or extrusion
optionally
followed by spheronisation or other similar known techniques. Generally
pellets are
more spherical in appearance than mini-tablets.
[0082] The term "immediate release" refers to a pharmaceutical dosage form
which releases levodopa immediately upon administration and will result in 80-
100
%, preferably 90 ¨ 100 % dissolution of the dose amount within one hour.
Dissolution method: USP apparatus I: 50 rpm; medium: 0.1 N hydrochloric acid,
750
ml.
[0083] The pharmaceutical dosage forms of the present invention can be
present in the form of monolayered or multilayered (for instance, bilayered or
trilayered tablets), minitablets, capsules, granules, pellets, or minitablets,
granules,
pellets or a combination of the same in a capsule or the like.
[0084] There are several different ways to prepare the dosage form(s)
according to the invention. In discussing the preparation of the dosage forms
we
will, for simplicity, refer to the COMT inhibitor as entacapone. However it
should be
understood that the methods described here for entacapone are equally suitable
for
use with another COMT inhibitor in which the amount of the COMT inhibitor is
adjusted as appropriate and as would be evident to the skilled person on the
basis of
the standard dose for the COMT inhibitor. Similarly, for simplicity the
aromatic amino
acid decarboxylase inhibitor is referred to as carbidopa, but it should be
understood
that the methods described are equally suitable for use with another AADC
inhibitor
in which the amount of AADC inhibitor is adjusted as appropriate.
[0085] One way
to prepare a dosage form according to the invention is to first
formulate carbidopa substantially separately from entacapone and levodopa
before
formulating into the dosage form, for example, in the manner disclosed in US
- 20 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
' 6,500,867 describing fixed oral combinations of entacapone, levodopa and
carbidopa, wherein carbidopa is substantially separated from entacapone and
levodopa. Another way is to first formulate entacapone substantially
separately from
levodopa and carbidopa before formulating into the dosage form. One particular
such way is to use separate entacapone-containing granules or granule
mixtures, for
example using the technologies disclosed in WO 2006/131591, and combine said
granules or granule mixtures with levodopa and AADC inhibitor either in a
fixed
combination formulation or as two separate dosage forms. A further way of
preparing dosage forms according to the invention is to first formulate part
of the
levodopa content with entacapone and a further part of the levodopa content
with
carbidopa, before formulating into the dosage form optionally together with a
further
part of the levodopa content added as such. A yet further way is to prepare a
mixture of levodopa, carbidopa and entacapone, of which any part may
optionally be
pre-processed, before formulating into the dosage form.
[0086] Thus, in one embodiment of the invention entacapone and carbidopa
are substantially separated from each other. There are several different
techniques
to accomplish said separation. It can be made, for instance, by granulating
levodopa
and entacapone together or separately and adding carbidopa as such (i.e. non-
granulated carbidopa, for example, in powder form) and/or as granules; or by
granulating levodopa and carbidopa and adding entacapone as such (i.e. non-
granulated entacapone, for example, in powder form) or in the form of
granules. Any
known granulation method, for example, wet granulation, melt granulation and
dry
granulation can be used, but preferably the granulation method is wet
granulation.
Suitable granulation methods are known in the art and suitable excipients are
listed
in, for instance in WO 2006/131591.
[0087] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
-21-
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
3.08:1.0 by weight, is provided comprising
(a) granulating substantial portion of entacapone and substantial portion of
levodopa
either together or separately
(b) optionally granulating all or any portion of carbidopa
(c) combining the product obtained in step (a) with the product of step (b) or
carbidopa as such or a mixture thereof; and
(d) formulating the product obtained in step (c) as well as the rest of
entacapone
and/or levodopa, if any, into tablets or minitablets or filling the same
directly into
capsules, sachets or a dispenser. This method is preferred, when flexibility
in the
release properties of the drug substances is required.
[0088] In a
particular embodiment of the invention a method for the preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating entacapone and levodopa either together or separately
(b) granulating carbidopa
(c) combining the product obtained in step (a) with the product of step (b);
and
(d) formulating the product obtained in step (c) into tablets or minitablets.
[0089] In a
particular embodiment of the invention a method for the preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating entacapone and levodopa either together or separately
(b) granulating from 5 to 80 % of carbidopa
- 22 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
(c) combining the product obtained in step (a) with the product of step (b)
and the
rest of carbidopa as such; and
(d) formulating the product obtained in step (c) into tablets or minitablets
or filling the
same directly into capsules, sachets or a dispenser.
[0090] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating entacapone and levodopa either together or separately
(b) granulating from 5 to 40 % of carbidopa
(c) combining the product obtained in step (a) with the product of step (b)
and the
rest carbidopa as such; and
(d) formulating the product obtained in step (c) into tablets or minitablets
or filling the
same directly into capsules, sachets or a dispenser.
[0091] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating entacapone and levodopa either together or separately
(b) granulating from 15 to 20 % of carbidopa
(c) combining the product obtained in step (a) with the product of step (b)
and the
rest carbidopa as such; and
(d) formulating the product obtained in step (c) into tablets or minitablets
or filling the
same directly into capsules, sachets or a dispenser.
- 23 -
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
[0092] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating entacapone and levodopa either together or separately
(b) combining the product obtained in step (a) with carbidopa as such; and
(c) formulating the product obtained in step (c) into tablets. This method
provides a
simple manufacturing process and a good stability for the product.
[0093] In one embodiment of the invention a method for the preparation of a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) formulating a substantial portion of entacapone and a substantial portion
of
levodopa either together or independently into granules, minitablets or
pellets
(b) formulating a substantial portion of carbidopa into granules, minitablets
or pellets;
and
(c) combining the product obtained in step (a) with the product of step (b)
and the
rest of the drug substances if any, and filling it into capsules, sachets or a
dispenser.
[0094] In one embodiment of the invention a method for the preparation of a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
- 24 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) formulating a substantial portion of entacapone and a substantial portion
of
levodopa either together or independently into granules, minitablets or
pellets
(b) formulating a substantial portion of carbidopa into granules, minitablets
or pellets;
and
(c) formulating the product obtained in step (a) and product of step (b) and
the rest of
the drug substances, if any, into a monolayered, bilayered, threelayered or a
multilayered tablet.
[0095] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating substantial portion of levodopa and substantial portion of
carbidopa
either together or separately
(b) optionally granulating all or any portion of entacapone
(c) combining the product obtained in step a) with the product obtained in
step (b), or
entacapone as such or a mixture thereof; and
(d) formulating the product obtained in step (c) an the rest of levodopa
and/or
carbidopa, if any, into tablets or minitablets or filling the same directly
into capsules,
sachets or a dispenser. Preferably, levodopa and carbidopa are granulated
together.
[0096] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
-25-
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating levodopa and carbidopa either together or separately
(b) granulating entacapone
(c) combining the product obtained in step a) with the product obtained in
step (b) ;
and
(d) formulating the product obtained in step (c) into tablets or minitablets
or filling it or
said minitablets into capsules, sachets or a dispenser. Preferably, levodopa
and
carbidopa are granulated together.
[0097] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating levodopa and carbidopa either together or separately
= (b) granulating from 5 to 100 % of entacapone
(c) combining the product obtained in step a) with the product obtained in
step (b);
and the rest of entacapone as such; and
(d) formulating the product obtained in step (c) into tablets or minitablets
or filling the
same directly into capsules, sachets or a dispenser.
[0098] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66
:1.0 to
3.08:1.0 by weight, is provided comprising
(a) granulating levodopa and carbidopa either together or separately
-26-
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
(b) granulating from 10 to 75 % of entacapone
(c) combining the product obtained in step a) with the product obtained in
step (b);
and the rest of entacapone as such; and
(d) formulating the product obtained in step (c) into tablets or minitablets
or filling the
same directly into capsules, sachets or a dispenser.
[0099] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating levodopa and carbidopa either together or separately
(b) granulating from 15 to 50 % of entacapone
(c) combining the product obtained in step a) with the product obtained in
step (b);
and the rest of entacapone as such; and
(d) formulating the product obtained in step (c) into tablets or minitablets
or filling the
same directly into capsules, sachets or a dispenser.
[00100] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) granulating levodopa and carbidopa either together or separately
(b) combining the product obtained in step (a) with entacapone as such; and
(c) formulating the product obtained in step (b) into tablets or minitablets.
[00101] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
- 27 -
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is
(a) formulating carbidopa and levodopa either together or independently into
granules, minitablets or pellets
(b) formulating entacapone into granules, minitablets or pellets; and filling
the
products obtained in steps (a) and (b) into capsules, sachets or a dispenser.
Preferabley, levodopa and carbidopa are formulated together.
[00102] Yet
another suitable way of separating entacapone and carbidopa has
been described in WO 2010/108845 disclosing a dosage form comprising a) a
first
mixture of 10 to 75 % by weight of the total amount of levodopa with all
entacapone
present in the composition and b) a second mixture of 25 to 90 A by weight of
total
levodopa with all carbidopa present in the composition and c) optionally, a
third
mixture comprising the remaining levodopa, if any. To accomplish the
separation of
carbidopa and entacapone, the two mixtures a) and b) are prepared such that
they
are not both in powder form. The same principles, manufacturing processes and
excipients as disclosed in WO 2010/108845 may be used to prepare the dosage
form also according to the present invention.
tO0i031¨ Thus, in one embodiment of the invention a method for the preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
a) preparing a first mixture of 10 to 75 % by weight of the total amount of
levodopa
with all entacapone present in the composition,
b) preparing a second mixture of 25 to 90 % by weight of total levodopa with
all
- 28 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
carbidopa present in the composition ;and
C) optionally preparing a third mixture comprising the remaining levodopa; and
d) formulating the products obtained in steps (a) and (b) and optionally (c)
independently into granules, tablets, minitablets or pellets and optionally
filling the
said granules, minitablets or pellets into capsules, sachets or a dispenser.
Preferably, when the products of step (a) and (b) are formulated together,
then (a)
and (b) are not both in powder form.
00104] 1ln one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66
:1.0 to
3.08:1.0 by weight, is provided comprising
a) granulating from 10 to 75 % by weight of the total amount of levodopa with
all
entacapone present in the composition,
b) granulating from 25 to 90 % by weight of total levodopa with all carbidopa
present
in the composition ;and
c) optionally preparing a third mixture comprising the remaining levodopa; and
d) formulating the products obtained in steps (a) and (b) and (c) if any into
tablets or
minitablets and optionally filling the said granules or minitablets into
capsules,
sachets or a dispenser.
[00105] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
a) preparing a first mixture of 30 to 90 % by weight of the total amount of
levodopa
- 29 -
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
with all entacapone present in the composition,
b) preparing a second mixture of 10 to 70 % by weight of total levodopa with
all
carbidopa present in the composition ;and
c) optionally preparing a third mixture comprising the remaining levodopa; and
d) formulating the products obtained in steps (a) and (b) and optionally (c)
independently into granules, tablets, minitablets or pellets and optionally
filling the
said granules, minitablets or pellets into capsules, sachets or a dispenser.
Preferably, when the products of step (a) and (b) are formulated together,
then
product (a) and (b) are not both in powder form.
[00106] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
a) preparing a first mixture of 50 to BO % by weight of the total amount of
levodopa
with all entacapone present in the composition,
b) preparing a second mixture of 20 to 50 % by weight of total levodopa with
all
carbidopa present in the composition ;and
c) optionally preparing a third mixture comprising the remaining levodopa; and
d) formulating the products obtained in steps (a) and (b) and optionally (c)
independently into granules, tablets, minitablets or pellets and optionally
filling the
said granules, minitablets or pellets into capsules, sachets or a dispenser.
Preferably, when the products of step (a) and (b) are formulated together,
then
product (a) and (b) are not both in powder form.
[00107] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
-30-
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
a) granulating 30 to 90 % by weight of the total amount of levodopa with all
entacapone present in the composition,
b) granulating of 10 to 70 % by weight of total levodopa with all carbidopa
present in
the composition ;and
c) optionally preparing a third mixture comprising the remaining levodopa; and
d) formulating the products obtained in steps (a) and (b) and (c) if any, into
tablets or
minitablets and optionally filling the said granules or minitablets into
capsules,
sachets or a dispenser.
[00108] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
a) granulating 50 to 80 A by weight of the total amount of levodopa with all
entacapone present in the composition,
b) granulating of 20 to 50 % by weight of total levodopa with all carbidopa
present in
the composition ;and
c) optionally preparing a third mixture comprising the remaining levodopa; and
d) formulating the products obtained in steps (a) and (b) and (c) if any, into
tablets or
minitablets and optionally filling the said granules or minitablets into
capsules,
sachets or a dispenser.
[00109] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
-31 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) preparing a mixture of optionally pre-processed levodopa, optionally pre-
processed carbidopa and optionally pre-processed entacapone,
(b) formulating the product obtained in step (a) into granules, tablets,
minitablets,
pellets and optionally filling said granules, minitablets or pellets into a
capsule,
sachet or a dispenser.
[00110] In a particular embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided comprising
(a) preparing a mixture of optionally pre-processed levodopa, optionally pre-
processed carbidopa and optionally pre-processed entacapone,
(b) compressing the product obtained in step (a) into tablets. This method
provides
a simple and robust manufacturing process, wherein also non-micronized drug
substances (for instance, medium sized or coarse entacapone) may be used.
[00111] In one embodiment of the invention an oral solid dosage form is
provided comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, allowing 80-100 % of levodopa to be released within one
hour in
a dissolution test (USP apparatus I (baskets) 50 rpm, medium: 0.1 N
hydrochloric
acid, volume 750 ml) from said dosage form.
- 32 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
[00112] In one embodiment of the invention an oral solid dosage form is
provided comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, allowing from 90 to 100 % of levodopa to be released
within one
hour in a dissolution test (USP apparatus I (baskets) 50 rpm, medium: 0.1 N
hydrochloric acid, volume 750 ml) from said dosage form.
[00113] In one embodiment of the invention an oral solid dosage form is
provided comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, allowing from 20 to 100% of carbidopa to be released
within
one hour in a dissolution test (USP apparatus I (baskets) 50 rpm, medium: 0.1
N
hydrochloric acid, volume 750 ml) from said dosage form.
[00114] In one embodiment of the invention an oral solid dosage form is
provided comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, allowing from 40 to 100% of carbidopa to be released
within
one hour in a dissolution test (USP apparatus I (baskets) 50 rpm, medium: 0.1
N
hydrochloric acid, volume 750 ml) from said dosage form.
[00115] In one embodiment of the invention an oral solid dosage form is
provided comprising
- 33 -
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, allowing from 20 to 100 % of entacapone to be released
within
60 minutes in a dissolution test (USP apparatus I (baskets) 125 rpm, medium:
phosphate buffer pH 5.5, volume 900 ml) from said dosage form.
[00116] In one embodiment of the invention an oral solid dosage form is
provided comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, allowing from 40 to 100 % of entacapone to be released
within
60 minutes in a dissolution test (USP apparatus I (baskets) 125 rpm, medium:
phosphate buffer pH 5.5, volume 900 ml) from said dosage form.
[00117] The dosage form according to the invention may include, for
instance
one or more of fillers, binders, disintegrants, solubility enhancers,
glidants, lubricants
(if applicable, for example, if tabletting) as well as other pharmaceutical
excipients.
The maximum amount of excipients is typically from 50 to 60% by weight of the
dosage form.
[00118] The amounts of the excipients depend on the choice of technology in
question and whether the same technology, for example, granulation is used to
formulate all drug substances. For example, in case wet granulation is used to
formulate all drug substances then the amount of the binder is typically from
about
0.1 % by weight to about 50 % by weight of the total weight of the dosage
form.-
[00119] The amount of disintegrant is typically from about 1 % by weight to
about 30 % by weight of the total weight of the dosage form. A typical amount
of a
solubility enhancer is from about 1 % by-weight to about 40 % by weight of the
total
weight of the dosage form. A typical amount of a diluent or filler is from
about 1 % by
- 34 -
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
weight to about 60 % by weight of the total weight of the dosage form. A
typical
amount of a glidant is from about 0.1 A by weight to about 20 % by weight of
the
total weight of the dosage form. A typical amount of a lubricant is from about
0.1 %
by weight to about 10 % by weight of the total weight of the dosage form. A
typical
amount of a release rate controlling excipient is from about 0.1 % by weight
to about
60 % by weight of the total weight of the dosage form. A typical amount of a
co-
processed excipient is from about 1 % by weight to about 60 % by weight of the
total
weight of the dosage form.
[00120] In one embodiment the dosage form according to the invention
comprises a diluents or a filler which may be used e.g. as a processing aid.
The
diluents or filler may be, for instance one or more of calcium carbonate
(Barcroft,
Cal-Carb, CalciPure, Destab, MagGran, Millicarb, Pharma-Carb, Precarb,
Sturcal,
Vivapres Ca), calcium phosphate, dibasic anhydrous (A- TAB, Di-Cafos A-N,
Emcompress Anhydrous, Fujicalin), calcium phosphate, dibasic dihydrate (Cafos,
Calipharm, Calstar, Di-Cafos, Emcompress), calcium phosphate tribasic (Tri-
Cafos,
TRI-CAL WG, TRI-TAB), calcium sulphate (Destab, Drierite, Snow White, Cal-Tab,
Compactrol, USG Terra Alba), cellulose powdered (Arbocel, Elcema, Sanacel,
Solka-Floc), silicified microcrystalline cellulose (ProSolv), cellulose
acetate,
compressible sugar (Di-Pac), confectioner's sugar, dextranes (Candex, Emdex),
dextrin (Avedex, Caloreen, Crystal Gum, Primogran W), dextrose (Caridex,
Dextrofin, Lycadex PF, Roferose, Tab fine D-I00), fructose (Advantose,
Fructamyl,
Fructofin, Krystar), kaolinLion, Sim 90), lactitol (Finlac ACX, Finlac DC,
Finlac MCX)
lactose (Aero Flo 20, Aero Flo 65, Anhydrox, CapsuLac, Fast-Flo, FlowLac,
GranuLac, InhaLac, Lactochem, Lactohale, Lactopress, Microfine, Microtose,
Pharmatose, Prisma Lac, Respitose, SacheLac, SorboLac, Super-Tab, Tablettose,
Wyndale, Zeparox), magnesium carbonate, magnesium oxide (MagGran MO),
isomalt (Galen IQ, Isomaltidex, Palatinit), maltodextrin (C*Dry MD, Glucidex,
Glucodry, Lycatab DSH, Maldex, Maltagran, Maltrin, Maltrin QD, Paselli MD 10
PH,
Star-Dri), maltitol (C*PharmMaltides, Maltisorb, D-maltitol, Maltit, Amalty,
Malbit)
maltose (Advantose 100), mannitol (Mannogem, Pearlitol), microcrystalline
cellulose
(Avicel PH, Celex, Celphere, Ceolus KG, Emcocel, Ethispheres, Fibrocel,
Pharmacel, Tabulose, Vivapur), polydextrose (Litesse), simethicone (Dow
Corning
-35-
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
Q7- 2243 LVA, Cow Corning Q7-2587, Sentry Simethicone), sodium alginate
(Kelcosol, Keltone, Protanal), sodium chloride (Alberger), sorbitol (Liponec
70-NC,
Liponic 76-NC, Meritol, Neosorb, Sorbifin, Sorbitol Instant, Sorbogem), starch
(Aytex
P, Fluftex W, Instant Pure-Cote, Melojel, Meritena Paygel 55, Perfectamyl
D6PH,
Pure-Bind, Pure- Cote, Pure-Dent, Pure-Gel, Pure-Set, Purity 21, Purity 826,
Tablet
White), pregelatinized starch (lnstastarch, Lycatab C, Lycatab PGS, Merigel,
National 78-1551, Pharma-Gel, Prejel, Sepistab ST 200, Spress B820, Starch
1500
G, Tablitz, Unipure LD, Unipure WG220), sucrose, trehalose and xylitol
(Klinit,
Xylifm, Xylitab, Xylisorb, Xylitolo).
[00121] In one embodiment the dosage form of the invention comprises a
binder.
The binder may be, for instance one or more of following: acacia, alginic acid
(Kelacid, Protacid, Satialgine H8), carbomer (Acritamer, Carbopol, Pemulen,
Ultrez),
carboxymethylcellulose sodium (Akucell, Aquasorb, Blanose, Finnfix, Nymcel,
Tylose), ceratonia (Meyprofleur), cottonseed oil, dextrin (Avedex, Caloreen,
Crystal
Gum, Primogran W), dextrose (Caridex, Dextrofm, Lycedex PF, Roferose, Tabfme
D-I00), gelatin (Cryogel, Instagel, Solugel), guar gum (Galactosol, Meprogat,
Meyprodor, Meyprofm, Meyproguar), hydrogenated vegetable oil type I (Akofine,
Lubritab, Sterotex, Dynasan P60, Softisan 154, Hydrocote, Lipovol,HS-K,
Sterotex
HM), hydroxyethyl cellulose (Alcoramnosan, Cellosize, Idroramnosan,
Liporamnosan, Natrosol, Tylose PHA), hydroxyethylmethyl cellulose (Culminal,
Tylopur MH, Tylopur MHB, Tylose, MB, Tylose MH, Tylose MHB), hydroxypropyl
cellulose (Klucel, Methocel, Nisso HPC), low substituted hydroxypropyl
cellulose,
hypromellose (Benecel MHPC, Methocel, Metolose, Pharmacoat, Spectracel 6,
Spectracel 15, Tylopur), methylcellulose (Benecel, Culminal MC), magnesium
aluminium silicate (Carrisorb, Gelsorb, Magnabite, Neusilin, Pharmsorb,
Veegum),
maltodextrin (C*Dry,MD, Glucidex, Glucodry, Lycatab DSH, Maldex, Maltagran,
Maltrin, Maltrin QD, Paselli MD 10 PH, Star-Dri) maltose (Advantose 100),
methylcellulose (Benecel, Culminal MC, Methocel, Metolose), microcrystalline
cellulose (Avicel PH, Celex, Celphere, Ceolus KG, Emcocel, Ethispheres,
Fibrocel,
Pharmacel, Tabulose, Vivapur), polydextrose (Litesse), polyethylene oxide
(Polyox),
polymethacrylates (Eastacryl 30D, Eudragit, Kollicoat MAE 30D, Kollicoat MAE
30DP), povidone (Kollidon, Plasdone), sodium alginate (Kelcosol, Keltone,
Protanal),
- 36 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
starch (Aytex P, Fluftex W, Instant Pure- Cote, Melojel, Meritena Paygel 55,
Perfectamyl D6PH, Pure-Bind, Pure-Cote, Pure-Dent, Pure-Gel, Pure-Set, Purity
21,
Purity 826, Tablet White), pregelatinized starch (lnstastarch, Lycatab C,
Lycatab
PGS, Merigel, National 78-1551, Pharma-Gel, Prejel, Sepistab ST 200, Spress
B820, Starch 1500 G, Tablitz, Unipure LD, Unipure WG 220), stearic acid
(Crodacid,
Emersol Hystrene, lndustrene, Kortacid 1895, Pristerene), sucrose and zein.
[00122] In one embodiment of the invention the binder is a binder suitable
for
use in hot melt granulation (hot melt binder). Such a binder may be, for
example one
or more of the following: Polyethylene glycol (Breox PEG, Carbowax, Hodag PEG,
Lutrol E), Stearic acid, Paraffin, Castor oil, hydrogenated (Castorwax,
Castorwax MP
70, Castorwax MP 80, Opalwax, Sinulsol), Carnauba wax, Candelilla wax,
Cottonseed oil, hydrogenated (Lubritab, Sterotex), glyceryl monostearate
(Advawax
140, Atmul 67, Citomulgin M, Estol 603, Hodag GMS, Myvaplex 600P), acetylated
glycerol monostearate, sorbitan monostearate (Capmul S, Liposorb S, Protachem
SMS, Span 60), hexadecyl palmitate, octadecyl stearate, glyceryl trimyristate
(Dynasan 114), glyceryl trilaurate (Dynasan 112), glyceryl tripalmitate
(Dynasan
116), glyceryl tristearate (Dynasan 118) and glyceryl behenate (Compritol 888
Ato).
[00123] In one embodiment the dosage form according to the invention
comprises a disintegrant. The disintegrant maybe, for instance one or more of
following: alginic acid (Kelacid, Protacid, Satialgine H8), calcium phosphate,
tribasic
(Tri-Cafos, TRI-CAL WG, TRI-TAB), carboxymethylcellulose calcium (ECG 505,
Nymcel ZSC), carboxymethylcellulose sodium (Akucell, Aquasorb, Blanose,
Finnfix,
Nymcel Tylose CB), colloidal silicon dioxide (Aerosil, Cab-O-Sil, Cab-O-Sil M-
5P,
Wacker HDK), croscarmellose sodium (Ac-Di-Sol, Explocel, Nymcel ZSX, Pharmacel
XL, Primellose, Solutab, Vivasol), crospovidone (Kollidon CL, Kollidon CL-M,
Polyplasdone XL, Polyplasdone XL-I0), docusate sodium, guar gum (Galactosol,
Meprogat, Meyprodor, Meyprofin, Meyproguar), low substituted hydroxypropyl
cellulose, magnesium aluminun silicate (Carrisorb, Gelsorb, Magnabite,
Neusilin,
Pharmsorb, Veegum), methylcellulose (Benecel, Culminal MC, Methocel,
Metolose),
microcrystalline cellulose (Avicel PH, Celex, Celphere, Ceolus KG, Emcocel,
Ethispheres, Fibrocel, Pharmacel, Tabulose, Vivapur), povidone (Kollidon,
Plasdone)
sodium alginate (Kelcosol, Keltone, Protanal), sodium starch glycolate
(Explotab,
- 37 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
Primojel, Vivastar P), polacrilin potassium (Amberlite IRP88), silicified
microcrystalline cellulose (ProSolv), starch (Aytex P, Fluftex W, Instant Pure-
Cote,
Melojel, Meritena, Paygel 55, Perfectamyl D6PH, Pure-Bind, Pure- Cote, Pure-
Dent,
Pure-Gel, Pure-Set, Purity 21, Purity 826, Tablet White) or pregelatinized
starch
(lnstanstarch, Lycatab C, Lycatab PGS, Merigel, National 78-1551, Pharma-Gel,
Prejel, Sepistab ST 200, Spress B820, Starch 1500 G, Tablitz, Unipure LD and
Unipure WG220).
[00124] In one embodiment the dosage form according to the invention
comprises a solubility enhancer. The solubility enhancer may be, for instance
one or
more of the following: cyclodextrins (Cavitron, Encapsin, Rhodocap, Kleptose),
glyceryl monostearate (Abracol SLG, Admul, Myvaplex 600P), lecithin, poloxamer
(Lutrol, Monolan, Pluronic), polyoxyethylene fatty acid esters (polysorbates)
(Tween),
polyoxyethylene castor oil derivatives (Cremophor series), docusate sodium
(Cropol), sodium lauryl sulphate (Elfan 240, Maprofix 563), sorbitan esters
(sorbitan
fatty acid esters) (Span), polyvinyl pyrrolidone, polyethylene glycol (PEG),
lauryl
macrogol glyceride (Gelucire) and d-alpha-tocophenyl PEG succinate (Vitamin E
TPGS NF).
[00125] In one embodiment the dosage form according to the invention
comprises a release rate controlling excipient. The release controlling
excipient may
be, for instance one or more of hydroxypropyl cellulose, hypromellose, hydroxy
ethyl
cellulose, ethyl cellulose, cellulose ethers, poly(ethylene oxide),
microcrystalline
cellulose, carbomer, carbomers, carbomer copolymer, povidone (Kollidon,
Plasdone)
polyvinyl acetate ¨povidone (Kollidon SR), fatty acids, fatty acid esters,
magnesium
stearate, calcium stearate, stearic acid, stearyl alcohol, glyceryl
monostearate
(Capmul GMS-50, Cutina GMS, lmwitor 191 and 900, Kessco GMS5 Lipo GMS 410,
450 and 600, Myvaplex 600P, Myvatex, Protachem GMS-450, Rita GMS, Stepan
GMS, Tegin, Tegin 503 and 515, Tegin 4100, Tegin M, Unimate GMS), glyceryl
behenate (Compritol 888 ATO), glyceryl palmitostearate Precirol ATO 5)
hydrogenated castor oil (Castorwax, Castorwax MP 70, Castorwax MP 80,
Croduret,
Cutina HR, Fancol, Simulsol 1293), hydrogenated vegetable oil type I (Akofine,
Lubritab, Sterotex, Dynasan P60, Softisan 154, Hydrocote, Lipovol HS-K,
Sterotex
HM),carnauba wax, shellac, rosin, zein, traganth gum, xanthan gum, guar gum,
-38 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
locust bean gum (Ceratoria). Other examples of suitable polymers include (but
are
not limited to) cellulose acetate, cellulose acetate phthalate, hypromellose
phthalate,
hypromellose acetate succinate, polyvinyl acetate, polyvinyl acetate
phthalate,
alginic acid and its salts like sodium alginate, potassium alginate, calcium
alginate,
propylene glycol alginate. Also a release rate controlling agent may be
acrylic acid
polymers and copolymers like methyl acrylate, ethyl acrylate, methyl
methacrylate
and/or ethyl methacrylate with copolymers of acrylic and methacrylic acid
esters
(Eudragit NE, Eudragit RL, Eudragit RS, Eudragit FS30D, Eudrgit L, Eudragit S,
Eudragit S100, Eudragit L100-55, RS30D, RL30D, NE30 D, Kollicoat MAE 30D,
Kollicoat MAE 30DP, Acryl EZE, Acryl EZE-MP, Eastacryl 30D) and the like and
any
mixture or combination thereof, cellulose acetate, cellulose diacetate,
cellulose
triacetate, cellulose acetate phthalate, polyvinyl acetate phthalates,
hydroxypropyl
methylcellulose phthalates, hydroxypropyl methylcellulose acetate succinates
LF,
hydroxypropyl methylcellulose acetate succinate HF, and others.
[00126] In one embodiment the dosage form according to the invention
comprises a glidant. The glidant may be, for instance one or more of the
following:
tribasic calcium phosphate (Tri-Cafos, TRI-CAL, TRI-TAB), calcium silicate,
cellulose, powdered (Arbocel, Elcema, Sanacel, Solka-Floc), colloidal silicon
dioxide
(Aerosil, Cab-O-Sil, Cab-O-Sil M-5P, Wacker HDK), magnesium silicate,
magnesium
trisilicate, starch (Aytex P, Fluftex W, Instant Pure-Cote, Melojel, Meritena,
Paygel
55, Perfectamyl D6PH, Pure- Bind, Pure-Cote, Pure-Dent, Pure-Gel, Pure-Set,
Purity
21, Purity 826, Tablet White) and talc (Altaic, Luzenac, Luzenac Pharma,
Magsil
Osmanthus, Magsil Star, Superiore).
[00127] In one embodiment the dosage form is a tablet or a core tablet and
a
lubricant may be used to improve the tabletting. The lubricant may be for
instance
one or more of following: calcium stearate (HyQual), glycerine monostearate
(Capmul GMS-50, Cutina GMS, lmwitor 191 and 900, Kessco GMS5 Lipo GMS 410,
450 and 600, Myvaplex 600P, Myvatex, Protachem GMS-450, Rita GMS, Stepan
GMS, Tegin, Tegin 503 and 515, Tegin 4100, Tegin M, Unimate GMS), glyceryl
behenate (Compritol 888 ATO), glyceryl palmitostearate Precirol ATO 5),
hydrogenated castor oil (Castorwax, Castorwax MP 70, Castorwax MP 80,
Croduret,
Cutina HR, Fancol, Simulsol 1293), hydrogenated vegetable oil type I (Akofine,
- 39 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
Lubritab, Sterotex, Dynasan P60, Softisan 154, Hydrocote, Lipovol HS-K,
Sterotex
HM), magnesium lauryl sulphate, magnesium stearate, medium-chain triglycerides
(Captex 300, Captex 355, Crodamol GTC/C, Labrafac CC, Miglyol 810, Miglyol
812,
Myritol, Neobee M5, Nesatol, Waglinol 3/9280), poloxamer (Lutrol, MonoIan,
Pluronic, Supronicm, Synperonic), polyethylene glycol (Carbowax, Carbowax
Sentry,
Lipo, Lipoxol, Lutrol E, Pluriol E), sodium benzoate (Antimol), sodium
chloride
(Alberger), sodium lauryl sulphate (Elfan 240, Texapon KI 2P), sodium stearyl
fumarate (Pruv), stearic acid (Crodacid E570, Emersol, Hystrene, Industrene,
Kortacid 1895, Pristerene), talc (Altaic, Luzenac, Luzenac Pharma, Magsil
Osmanthus, Magsil Star, Superiore), sucrose stearate (Surfhope SE Pharma D-
1803
F) and zinc stearate (HyQual).
[00128] In one embodiment the dosage form according to the invention
comprises as co-processed excipients any combinations of these components
which
by their functions for improv said properties. Some of them are commercially
available like cellulose and silicified microcrystalline (ProSolv) or
microcrystalline
cellulose - silicon dioxide ¨ sodium starch glycolate and sodium stearyl
fumarate
(ProSolv EASYtab).
[00129] In one embodiment of the invention the tablet, minitablet, granule
and/or
the pellet disclosed herein may be coated. In one embodiment of the invention
the
coating comprises one or more of the following polymers:a cellulose
derivative,polyvinyl alcoholõ polyethylene glycols, acrylate polymers or a
sugar
derivative. Preferably, a water based coating is used. The coating may
comprise
plasticizers, dyes, colour lakes, or pigments, such as iron oxides, for
instance yellow
or red irons oxides and titanium dioxide.
[00130] Entacapone used in the dosage form of the invention is preferably a
substantially pure (E)-isomeric form the preparation of which has been
disclosed in
US 5,135,950. The (E)-isomer may take different polymorphic forms, e.g.
polymorph
A disclosed in US 5,135,950 or polymorph D disclosed in WO 2005/063696.
[00131] The water solubility of entacapone is rather slow. Due to poor
solubility,
the dissolution rate of entacapone can be a limiting factor for the absorption
of
entacapone in the gastrointestinal tract. WO 2006/131591 discloses that in
order to
facilitate the absorption, entacapone having reduced particle size (i.e. at
least 90 %
- 40 -
CA 02784819 2012-06-18
WO 2011/107653
PCT/F12011/000013
of entacapone particles have a diameter less than 55 microns e.g. less than 35
microns) is preferably used when making granules comprising entacapone. The
specific surface area (SSA) of such fine particles of entacapone is typically
higher
than 2.0 m2 /g.
[00132] Thus, in
one embodiment of the invention a method for the preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from :1.0 to
3.08:1.0 by weight, is provided, wherein in the preparation of said dosage
form
entacapone has been used having specific surface area of from 2 m2/g to 20
m2/g.
[00133] In one
embodiment of the invention a method for the preparation of a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0by weight, is provided, wherein in the preparation of said dosage form
entacapone has been used having specific surface area of from 2.2 m2/g to 7
m2/g.
[00134] Entacapone
particles of reduced particle size, however, have tended to
cause manufacturing problems. Potential problems related to fine particle size
include poor flowability and agglomeration which may result in compromised
content
uniformity (i.e. the reproroducible amount of entacapone between different
units).
The use of coarser particle size would therefore be beneficial. Such a coarser
particle size could be used, for example, in direct compression which is
advantageous, as direct compression is an inexpensive and efficient
manufacturing
process. It has now been surprisingly found out by the applicants that is not
necessary (but it is still possible) to use such a small particle size of
entacapone
when preparing the dosage forms according to the invention. Quite to the
contrary,
- 41 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
when using particle sizes of entacapone larger than the ones disclosed in WO
2006/131591 it is possible to influence the pharmacokinetic profile of
levodopa by
reducing the time to Cmax i.e. Tmax. Reduced Tmax could be highly valuable to
a
patient who has troublesome early-morning parkinsonian symptoms such as
akinesia, rigidity and foot dystonia.
[00135] Thus, in one embodiment of the invention a method for the
preparation
of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided, wherein in the preparation of said dosage
form
entacapone has been used having specific surface area of from 0.2 m2/g to less
than
2 m2/g. Entacapone particles having a SSA from 0.2 m2/g to 2 m2/g are
considered to
consist mainly of medium sized particles.
[00136] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided, wherein in the preparation of said dosage
form
entacapone has been used having specific surface area of from 0.2 m2/g to 1.0
m2/g.
[00137] Still in another embodiment of the invention a method for the
preparation of a oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
-42 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
3.08:1.0 by weight, is provided, wherein in the preparation of said dosage
form
entacapone has been used having specific surface area of from 001 to less than
0.2
m2/g. Entacapone particles having a SSA from 0.01 m2 to 02 m 2 are considered
to
consist mainly of coarse sized particles.
[00138] The particle size of levodopa for use in the dosage form of the
present
invention may be a particle size as typically used in formulations comprising
levodopa. The particle size of commercially available levodopa may generally
be
suitable.
[00139] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
('ii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion
of entacapone to carbidopa in said dosage form ranges from 0.66:1.0 to
3.08:1.0by
weight, is provided, wherein in the preparation of said dosage form entacapone
has
been used having specific surface area of from 0.1 to 0.2 m2/g.
[00140] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided, wherein in the preparation of said dosage
form
levodopa has been used having specific surface area of from 0.1 to 1.0 m2/g.
[00141] The particle size of carbidopa for use in the dosage form of the
present
invention may be a particle size as typically used in formulations comprising
carbidopa.
[00142] In one embodiment of the invention a method for the preparation of
a
oral solid dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 200 mg,
- 43 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
(ii) carbidopa in an amount ranging from 65 mg to 150 mg or a therapeutically
equivalent amount of another aromatic amino acid decarboxylase inhibitor, and
(iii) entacapone in an amount ranging from 100 mg to 200 mg, wherein the
proportion of entacapone to carbidopa in said dosage form ranges from 0.66:1.0
to
3.08:1.0 by weight, is provided, wherein in the preparation of said dosage
form
carbidopa has been used having specific surface area of from 0.5 to 10 m2/g.
[00143] The SSA values are measured using three-point nitrogen gas
adsorption
according to the BET (Brunauer-Emmett-Teller) technique well known in the art
(e.g.
using Coulter SA3100, Coulter Corp. or TriStar 3000, Micromeritics, or other
corresponding equipment).
[00144] The entacapone particles used in the dosage form(s) as well as in
the
preparation thereof according to this disclosure can be produced by any method
used in the art for obtaining particles with a desired specific surface area
and/or
particles size distribution. Thus, they may be obtained directly from the
production
scale processes (e.g. by direct crystallization) or reducing the particle size
of said
entacapone particles for example mechanically (e.g. by milling, for instance
by a ball
mill, a fluid energy attrition mill or a jet mill), by ultrasonic means and/or
by
fractionating. As a general textbook reference on providing particles of
desired size
as well as to manufacturing technologies mentioned herein a reference is made
to
Remington's Pharmaceutical Sciences, 18th ed, 1990, Mack Publishing Company,
Easton, Pennsylvania 18042. Suitable manufacturing technologies may be also
found in Pharmaceutics the Science of Dosage Form Design Ed. M.E. AuIton,
2000..
[00145] The particle size of aromatic amino acid decarboxylase inhibitor
other
than carbidopa and of COMT inhibitor other than entacapone may similarly be
the
size typically used in formulations comprising these substances, and
commerciallyavailable materials may be of a suitable particle size.
[00146] It is to be understood that whenever a method for the preparation a
given dosage form is mentioned herein in the context of this disclosure it is
meant
that this invention also comprises the dosage forms obtainable using said
method.
Thus, the present invention also relates to dosage forms, particularly oral
solid
dosage forms, including single unit dosage forms and multiple-unit dosage
forms,
comprising granules, tablets, minitablets, pellets, capsules, sachets or
dispensers
- 44 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
obtainable by the methods described above, particularly the methods disclosed
in
any of paragraphs [085] to [110] or [132] to [143]. It is further to be
understood that
any specific disclosure herein regarding amounts, ranges, excipients, particle
size,
manner of formulation, parameters, etc may be applied, as would be evident to
the
skilled person, to any embodiment disclosed herein whether methods (e.g..
methods
for the treatment of the body or methods of manufacture) or products, e.g.
dosage
forms.
[00147] The present disclosure also provides a kit for simultaneous or
sequential
administration of levodopa, carbidopa or a therapeutically equivalent amount
of
another aromatic amino acid decarboxylase inhibitor, and entacapone, a
moderately
potent COMT inhibitor, or a highly potent COMT inhibitor in the amounts
described
above. The kit may comprise the levodopa, aromatic amino acid decarboxylase
inhibitor (such as carbidopa) and COMT inhibitor (such as entacapone) in any
combination. Thus, the kit may suitably be comprised of oral solid dosage
forms in
any combination of single and multi-unit dosage forms as defined above. Thus,
in
one embodiment, a kit may be comprised of all single oral dosage forms as
defined
above. For example, such a kit might comprise a number of tablets, each of
which
comprise levodopa, carbidopa and entacapone, for individual administration at
set
time intervals.
[00148] In another embodiment, a kit may be comprised of all multi-unit
dosage
forms in the form of individual tablets containing the drug substances. By way
of
example, such a kit could comprise entacapone in one tablet and a separate
tablet
containing levodopa and carbidopa for sequential administration. In a further
embodiment, a kit may comprise multi-unit dosage forms in the form of a
plurality of
oral solid units (i.e. multiple unit or multi-particulate dosage forms), e.g.
a capsule,
sachet or dispenser filled with minitablets, granules or pellets. In another
embodiment, a kit may comprise one or more single oral dosage forms and one or
more multi-unit dosage forms. Thus, a further example of a kit may comprise
(1) a
single oral dosage form comprising a COMT inhibitor, levodopa and carbidopa
and
(2) further oral solid dosage forms (single oral dosage forms or multi-unit
dosage
forms) for separate administration which comprise levodopa and carbidopa and
-45 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
optionally the same COMT inhibitor or a different COMT inhibitor, such as
entacapone.
[00149] The present disclosure will be illustrated by the following non-
limiting
examples.
EXAMPLES
Example 1
[00150] The primary objective of the study was to evaluate the effects of
different
carbidopa dose levels on the pharmacokinetics (PKs) of levodopa with and
without
concomitant administration of entacapone. This was the first study to evaluate
the
effect of the combinations in a repeated dose setting in human subjects.
Pharmacokinetics of levodopa in the presence of AADC and COMT inhibition with
substances like carbidopa and entacapone is complex and difficult to model
based
on single dose PK data in humans, or animal models. However, it has been shown
earlier that levodopa PK in healthy subjects is similar to that seen in PD
patients and
therefore the results of this study indicate how the levodopa PK will be in PD
patients
and how the levodopa PK will predict symptom control of PD.
[00151] A total of 25 human subjects were enrolled into the study. The
study
subjects were randomly allocated to receive either 200 mg of entacapone or
corresponding placebo in each treatment period. Entacapone, or a corresponding
placebo, was administered concomitantly with 100 mg of levodopa and 25 mg of
carbidopa at 3.5-hour intervals 4 times a day. In addition, the study subjects
received in a randomised order in each treatment period one of the additional
dose
levels (0 mg, 25 mg, and 75 mg) of carbidopa.
[00152] There were 3 treatment periods, one for each carbidopa dose level
and
for the same subjects with cross-over design so that each subject participated
for the
3 periods. There were two groups with the same carbidopa doses, one group with
and one group without concomitant entacapone administration. By this study
design,
the effect of entacapone on carbidopa dose escalation and subsequently to
levodopa
PK could be assessed in repeated dose setting in humans.
[00153] Dose combinations were:
A: Entacapone 200 mg + levodopa 100 mg + carbidopa 25 mg
- 46 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
B: Entacapone 200 mg + levodopa 100 mg + carbidopa 50 mg
C: Entacapone 200 mg + levodopa 100 mg + carbidopa 100 mg
E: Levodopa 100 mg + carbidopa 25 mg
F: Levodopa 100 mg + carbidopa 50 mg
G: Levodopa 100 mg + carbidopa 100 mg
[00154] After the first and last dose of the day, the whole levodopa and
carbidopa plasma profiles were assessed and after the second and third dose
only
the minimum concentrations (just before the next dose at 3.5 and at 7.0 hours)
were
assessed. The results concerning levodopa are given in Figure 1 and the
results
concerning carbidopa are given in Figure 2.
[00155] The results demonstrate that in repeated dosing regimen, and with
the
presence of entacapone, increasing the carbidopa dose will significantly
improve
levodopa pharmacokinetics in human subjects. Without entacapone, the carbidopa
dose increase did not have such an effect. This means that changing the ratios
of
the three concomitantly (i.e. simultaneously) or sequentially administered
drugs,
levodopa pharmacokinetics and subsequently treatment of signs and symptoms of
Parkinson's disease can be significantly improved
Example 2
[00156] The primary objective of the study was to evaluate the effects of
different
carbidopa dose levels on the pharmacokinetics (PKs) of levodopa with
concomitant
administration of different entacapone dose levels and with the moderately
potent
COMT inhibitor tolcapone.
[00157] The study subjects were randomly allocated to receive either
increasing
doses of entacapone or standard dose of tolcapone combined with increasing
doses
of carbidopa in each treatment period, a total of 12 different dose
combinations.
Entacapone was administered concomitantly with 100 mg of levodopa and 25 mg of
carbidopa at 3.5-hour intervals 4 times a day and tolcapone 3 times a day. In
addition, the study subjects received increasing dose levels of carbidopa.
[00158] There were three groups, one for each carbidopa dose level, and 4
treatment periods in each group, one for each entacapone dose level or for
tolcapone and for the same subjects with cross-over design so that one subject
participated for the 4 periods. By this study design the effect of entacapone
and
- 47 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
tolcapone on carbidopa dose escalation and subsequently to levodopa PK could
be
assessed in repeated dose setting in humans.
[00159] After each levodopa dose of the day, the levodopa plasma profile
was
assessed. The levodopa plasma concentrations after entacapone dose escalation
and tolcapone standard dose and with increased carbidopa dose are given in
Figure
3.
[00160] The results demonstrate that in repeated dosing regimen, and with
the
increased COMT-inhibition either by increasing the COMT-inhibitor dose or by
using
a more potent COMT-inhibitor, increasing the carbidopa dose will significantly
improve levodopa pharmacokinetics in human subjects. This means that changing
the ratios of the three concomitantly (i.e. simultaneously) or sequentially
administered drugs, levodopa pharmacokinetics and subsequently treatment of
signs
and symptoms of Parkinson's disease can be significantly improved.
Example 3
[00161] The examples of suitable entacapone/levodopa/carbidopa tablet
formulations are described in Tables 1 to 2 (formulations 1 to 4). The tablets
are
prepared by adding carbidopa separately as granules into the formulation.
Accordingly, entacapone and levodopa are granulated together with maize
starch,
mannitol, croscarmellose sodium and povidone in a high shear mixer. Carbidopa
is
wet granulated separately with maize starch, mannitol, croscarmellose sodium,
and
povidone in a high shear mixer. The dry entacapone/levodopa granules, the dry
carbidopa granules, croscarmellose sodium, mannitol (and castor oil,
hydrogenated,
in formulations 3 to 4), and magnesium stearate are mixed together and the
mass
obtained are compressed to tablets and coated with HPMC-coating containing a
color pigment.
- 48 -
CA 02784819 2012-06-18
WO 2011/107653 PCT/F12011/000013
TABLE 1. Proposed dosage forms of entacapone/levodopa/carbidopa 100/100/80
(Formulation 1) and 200/100/80 (Formulation 2) tablet.
Core tablet: Formulation 1 Formulation 2
mg / tablet mg / tablet
Entacapone 100.0 200.0
Levodopa 100.0 100.0
Carbidopa monohyd rate 86.5 86.5
(corresponds to anhydrate
80.0 mg)
Maize starch 77.0 107.0
Mannitol 141.3 159.7
Croscarmellose sodium 24.3 31.4
Povidone 32.4 47.9
Magnesium stearate 8.5 10.5
Theoretical weight of the 570.0 743.0
core tablet
HPMC-coating containing 17.0 21.0
color pigments
Theoretical weight of the 587.0 764.0
coated tablet
TABLE 2. Proposed dosage forms of entacapone/levodopa/carbidopa 100/100/80
(Formulation 3) and 200/100/80 (Formulation 4) tablet.
Core tablet: Formulation 3 Formulation 4
mg/tablet mg/tablet
Entacapone 100.0 200.0
Levodopa 100.0 100.0
Carbidopa monohydrate 86.5 86.5
(respond carbidopa 80.0
=
mg)
Maize starch 77.0 107.0
Mannitol 152.7 173.7
C rosca rmel lose sodium 12.9 17.4
Castor oil, hydrogenated 3.0 4.0
Povidone 32.4 47.9
Magnesium stearate 8.5 10.5
Theoretical weight of the 573.0 747.0
core tablet
HPMC-coating containing 17.0 21.0
color pigments
Theoretical weight of the 590.0 768.0
coated tablet
- 49 -
